|

ADG126 Clinical Trials

5 actively recruiting trials across 4 locations

▲ +1 trial since July 2026

Pipeline

Phase 1: 1Phase 2: 1Phase 1/2: 3

Top Sponsors

  • Sanofi1
  • National University Hospital, Singapore1
  • Incyte Corporation1
  • Hoffmann-La Roche1
  • Adagene Inc1

Indications

  • Cancer5
  • Advanced Liver Cancers1
  • Advanced/Metastatic Solid Tumors1
  • Locally Advanced Colorectal Cancer1
  • Metastatic Solid Tumors1

Other1 trial

Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer
Phase 2

Scottsdale, Arizona1 trial

ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Honor Health Research Institute

Phase 1/2

Costa Mesa, California1 trial

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

UC Irvine Medical Center

Phase 1/2

Los Angeles, California1 trial

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

The Angeles Clinic and Research Institute

Phase 1

Newark, Delaware1 trial

A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

Christiana Care Health System - Newark- Site Number : 8400011

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.